When you stop taking Eliquis, your blood loses its extra protection against clotting within about 24 hours of your last dose. What happens next depends heavily on why you were taking it. For some people, stopping is a planned, safe transition after a temporary clot risk has passed. For others, particularly those with atrial fibrillation or unexplained blood clots, stopping can sharply increase the chance of a stroke or new clot, especially in the first few weeks.
How Quickly Eliquis Leaves Your System
Eliquis has an apparent half-life of about 12 hours during regular use. That means roughly half the drug clears your body every 12 hours. After your final dose, the anticoagulant effect persists for approximately 24 hours, or about two half-lives. By 48 hours, almost all of the drug’s clot-preventing activity is gone.
This relatively quick clearance is one reason Eliquis doesn’t require blood monitoring the way older blood thinners like warfarin do. But it also means your protection disappears fast once you stop. There’s no gradual tapering effect. You go from fully anticoagulated to unprotected in roughly a day.
The Rebound Clotting Risk
One of the most important things to understand is that the weeks immediately after stopping carry the highest risk. Research from a registry tracking patients with atrial fibrillation found that the hazard of a blood clot in the first 30 days after stopping was nearly 7 times higher than in later months. The median time to a clotting event was just 14 days after discontinuation. Some researchers believe this reflects a “rebound hypercoagulability,” where the clotting system overcompensates once the drug is removed. Others think the underlying condition simply reasserts itself quickly.
Whatever the mechanism, the pattern is consistent. Clinical trials of Eliquis, along with other drugs in its class, have observed a similarly increased stroke risk following discontinuation. After that initial high-risk window, the clotting risk gradually settles back to whatever your baseline risk was before you started the medication.
Risk Depends on Why You Were Taking It
The consequences of stopping vary dramatically based on your original diagnosis.
Clots Caused by a Temporary Trigger
If your blood clot happened because of a clear, reversible cause (surgery, a long flight, a broken leg requiring immobilization), stopping after the standard 3 to 6 months of treatment carries a low risk of recurrence. For clots triggered by surgery specifically, the annualized recurrence rate is less than 1%. In these cases, stopping on schedule is the expected plan, not a concern.
Unprovoked Clots
If your clot appeared without an obvious trigger, the picture changes considerably. A large meta-analysis published in The BMJ found that after stopping anticoagulation for a first unprovoked clot, about 10 out of every 100 people experienced a recurrence within the first year. By 5 years, the cumulative recurrence rate reached 25%. By 10 years, it climbed to 36%. That risk is front-loaded: the first year is the most dangerous, with rates dropping from about 10 per 100 person-years in year one to roughly 3 per 100 person-years by years 6 through 10. Current guidelines suggest that people with unprovoked clots may benefit from staying on anticoagulation indefinitely.
Persistent Risk Factors
People with ongoing conditions that raise clot risk, such as inflammatory bowel disease, autoimmune disorders, active cancer, or chronic immobility, face higher recurrence rates than those with temporary triggers. For these patients, continuing anticoagulation beyond 6 months is often reasonable because the underlying risk factor never goes away.
Atrial Fibrillation
If you take Eliquis because of atrial fibrillation, stopping removes your primary defense against stroke. The risk is especially significant for people with higher stroke risk scores. Patients with a CHA2DS2-VASc score above 2 (a scoring system based on age, sex, history of stroke, heart failure, high blood pressure, diabetes, and vascular disease) face a meaningful increase in stroke risk when they stop. For most people with AFib, Eliquis is intended as a lifelong medication.
Stopping Before Surgery
Planned surgical stops are common and follow specific timing guidelines to balance bleeding risk against clot risk.
- Minor procedures (dental extraction, skin lesion removal): Skip one dose, either the morning of or the evening before. No extended interruption needed.
- Low-to-moderate risk procedures (gallbladder removal, hernia repair): Stop Eliquis one day before, giving roughly 30 to 36 hours for the drug to clear.
- Higher risk surgeries (joint replacement, cancer surgery): Stop two days before, allowing 60 to 68 hours of clearance.
- Spinal anesthesia or spinal procedures: Stop three days before the procedure.
Your surgical team will tell you exactly when to take your last dose and when to restart. In most cases, Eliquis is restarted as soon as bleeding risk is acceptably low, often within a day or two of the procedure. The goal is to keep the gap as short as possible. For patients at very high clot risk (recent clot within 3 months, certain mechanical heart valves, or high-risk atrial fibrillation), doctors sometimes use injectable blood thinners to “bridge” the gap, though the evidence for this approach is still evolving.
Warning Signs to Watch For
After stopping Eliquis for any reason, you should know the symptoms of new clot formation. A clot in a deep leg or arm vein typically causes swelling, pain or tenderness in the affected limb, skin that looks redder or darker than surrounding areas, and warmth over the swollen area. These symptoms usually develop on one side only.
A clot that travels to the lungs is a medical emergency. Signs include sudden difficulty breathing (whether you’re active or resting), sharp chest pain that may radiate to your jaw, neck, shoulder, back, or arm, and pain that worsens when you inhale. If you notice any combination of these symptoms after stopping Eliquis, call 911 immediately. Clots in the lungs can be fatal, and the first hours matter.
Why You Should Never Stop on Your Own
The Eliquis prescribing label carries a boxed warning, the FDA’s most serious alert, about premature discontinuation. Stopping without medical guidance puts you at risk during the most dangerous window: those first 2 to 4 weeks when rebound clotting risk peaks. Even if you’re experiencing side effects like bruising or minor bleeding, switching to a different medication is almost always safer than simply stopping.
If cost is the barrier, manufacturer assistance programs and generic versions of apixaban (the active ingredient in Eliquis) exist. If you’ve missed doses, don’t double up. Take the next scheduled dose and let your prescriber know. The short half-life means even a brief gap leaves you unprotected, so consistency matters more with Eliquis than with longer-acting blood thinners.